Targeted delivery of miR-200c/DOC to inhibit cancer stem cells and cancer cells by the gelatinases-stimuli nanoparticles

Biomaterials

Volumn 34, Issue 29, 2013, Pages 7191-7203

  Liu, Qin ^a   Li, Ru Tian ^a   Qian, Han Qing ^b   Wei, Jia ^a   Xie, Li ^a   Shen, Jie ^a   Yang, Mi ^a   Qian, Xiao Ping ^a   Yu, Li Xia ^a   Jiang, Xi Qun ^b   Liu, Bao Rui ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^b NANJING UNIVERSITY   (China)

Author keywords

Cancer stem cells; Drug delivery; EMT; MiR 200c; Nanoparticles

Indexed keywords

ANTITUMOR EFFECT; CANCER STEM CELLS; EMT; INTRAVENOUS ADMINISTRATION; MIR-200C; NANOPARTICLE (NPS); SYNERGETIC EFFECT; TARGETED DELIVERY;

CYTOTOXICITY; DRUG DELIVERY; DRUG PRODUCTS; GENE EXPRESSION; GLYCOPROTEINS; MAMMALS; NANOPARTICLES; NUCLEIC ACIDS; STEM CELLS; TUMORS;

DISEASES;

BETA TUBULIN; DOCETAXEL; GELATINASE; HERMES ANTIGEN; MICRORNA 200C; NANOPARTICLE; NUCLEIC ACID; UVOMORULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER STEM CELL; CANCER SURVIVAL; CELL INVASION; CELL MIGRATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG EFFECT; DRUG RELEASE; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CANCER; SURVIVAL TIME; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; GELATINASES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; NANOPARTICLES; NEOPLASTIC STEM CELLS; STOMACH; STOMACH NEOPLASMS; TAXOIDS; TUBULIN;

MUS; MUS MUSCULUS;

EID: 84879604991     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.06.004     Document Type: Article

References (35)

1. Louvet C., André T., Tigaud J., Gamelin E., Douillard J.Y., Brunet R., et al. Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. JClin Oncol 2002, 20:4543-4548.
2. Montero A., Fossella F., Hortobagyi G., Valero V. Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol 2005, 6:229-239.
3. Al-Lazikani B., Banerji U., Workman P. Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol 2012, 30:679-692.
4. Turner N.C., Reis-Filho J.S. Genetic heterogeneity and cancer drug resistance. Lancet Oncol 2012, 13:e178-e185.
5. Bhatia S., Frangioni J.V., Hoffman R.M., Iafrate A.J., Polyak K. The challenges posed by cancer heterogeneity. Nat Biotechnol 2012, 30:604-610.
6. Gupta P.B., Chaffer C.L., Weinberg R.A. Cancer stem cells: mirage or reality?. Nat Med 2009, 15:1010-1012.
7. Gupta P.B., Onder T.T., Jiang G., Tao K., Kuperwasser C., Weinberg R.A., et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009, 138:645-659.
8. Wang Z., Li Y., Ahmad A., Azmi A.S., Kong D., Banerjee S., et al. Targeting miRNAs involved in cancer stem cell and EMT regulation: an emerging concept in overcoming drug resistance. Drug Resist Updat 2010, 3:109-118.
9. Radisky D.C., LaBarge M.A. Epithelial-mesenchymal transition and the stem cell phenotype. Cell Stem Cell 2008, 2:511-512.
10. Floor S., van Staveren W.C., Larsimont D., Dumont J.E., Maenhaut C. Cancer cells in epithelial-to-mesenchymal transition and tumor-propagating-cancer stem cells: distinct, overlapping or same populations. Oncogene 2011, 30:4609-4621.
11. Mani S.A., Guo W., Liao M.J., Eaton E.N., Ayyanan A., Zhou A.Y., et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715.
12. Garofalo M., Romano G., Di Leva G., Nuovo G., Jeon Y.J., Ngankeu A., et al. EGFRand MET receptor tyrosine kinase-altered microRNA expression inducestumorigenesis and gefitinib resistance in lung cancers. Nat Med 2012, 18:74-82.
13. Kasinski A.L., Slack F.J. Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer 2011, 11:849-864.
14. Hwang H.W., Mendell J.T. MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer 2007, 96(Suppl.):R40-R44.
15. Kutanzi K.R., Yurchenko O.V., Beland F.A., Checkhun V.F., Pogribny I.P. MicroRNA-mediated drug resistance in breast cancer. Clin Epigene 2011, 2:171-185.
16. Dykxhoorn D.M. MicroRNAs and metastasis: little RNAs go a long way. Cancer Res 2010, 70:6401-6406.
17. Korpal M., Kang Y. The emerging role of miR-200 family of microRNAs in epithelial-mesenchymal transition and cancer metastasis. RNA Biol 2008, 5:115-119.
18. Li Y., VandenBoom T.G., Kong D., Wang Z., Ali S., Philip P.A., et al. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res 2009, 69:6704-6712.
19. Cochrane D.R., Spoelstra N.S., Howe E.N., Nordeen S.K., Richer J.K. MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. Mol Cancer Ther 2009, 8:1055-1066.
20. Liu Q., Li R.T., Qian H.Q., Yang M., Zhu Z.S., Wu W., et al. Gelatinase-stimuli strategy enhances the tumor delivery and therapeutic efficacy of docetaxel-loaded poly(ethylene glycol)-poly(varepsilon-caprolactone) nanoparticles. Int J Nanomedicine 2012, 7:281-295.
21. Wang Y., Gao S., Ye W.H., Yoon H.S., Yang Y.Y. Co-delivery of drugs and DNA from cationic core-shell nanoparticles self-assembled from a biodegradable copolymer. Nat Mater 2006, 5:791-796.
22. Liu Z., Chen K., Davis C., Sherlock S., Cao Q., Chen X., et al. Drug delivery with carbon nanotubes for invivo cancer treatment. Cancer Res 2008, 68:6652-6660.
23. Sève P., Mackey J., Isaac S., Trédan O., Souquet P.J., Pérol M., et al. Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol Cancer Ther 2005, 4:2001-2007.
24. Kavallaris M., Burkhart C.A., Horwitz S.B. Antisense oligonucleotides to class III beta-tubulin sensitize drug-resistant cells to Taxol. Br J Cancer 1999, 80:1020-1025.
25. Thiery J.P. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002, 2:442-454.
26. Wells A., Yates C., Shepard C.R. E-cadherin as an indicator of mesenchymal to epithelial reverting transitions during the metastatic seeding of disseminated carcinomas. Clin Exp Metastasis 2008, 25:621-628.
27. Shimono Y., Zabala M., Cho R.W., Lobo N., Dalerba P., Qian D., et al. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell 2009, 138:592-603.
28. Takaishi S., Okumura T., Tu S., Wang S.S., Shibata W., Vigneshwaran R., et al. Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells 2009, 27:1006-1020.
29. Chen W., Zhang X., Chu C., Cheung W.L., Ng L., Lam S., et al. Identification of CD44+ cancer stem cells in human gastric cancer. Hepatogastroenterology 2013, 60(127).
30. Bjorklund M., Koivunen E. Gelatinase-mediated migration and invasion of cancer cells. Biochim Biophys Acta 2005, 1755:37-69.
31. Pannuti A., Foreman K., Rizzo P., Osipo C., Golde T., Osborne B., et al. Targeting Notch to target cancer stem cells. Clin Cancer Res 2010, 16:3141-3152.
32. Takebe N., Harris P.J., Warren R.Q., Ivy S.P. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol 2011, 8:97-106.
33. Yokoyama K., Kamata N., Fujimoto R., Tsutsumi S., Tomonari M., Taki M., et al. Increased invasion and matrix metalloproteinase-2 expression by Snail-induced mesenchymal transition in squamous cell carcinomas. Int J Oncol 2003, 2:891-898.
34. Bourguignon L.Y., Gunja-Smith Z., Iida N., Zhu H.B., Young L.J., Muller W.J., et al. CD44v(3,8-10) is involved in cytoskeleton-mediated tumor cell migration and matrix metalloproteinase (MMP-9) association in metastatic breast cancer cells. JCell Physiol 1998, 176:206-215.
35. Honeth G., Bendahl P.O., Ringnér M., Saal L.H., Gruvberger-Saal S.K., Lövgren K., et al. The CD44+/CD24- phenotype is enriched in basal-like breast tumors. Breast Cancer Res 2008, 10:R53.